“Confirmed” Aviva Plc buys more shares in Immupharma Plc

ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, confirmed to DirectorsTalk that it has received a TR-1 by Aviva plc and its subsidiaries confirming its increased holding in ImmuPharma to 11,332,848 Ordinary Shares.

This increased holding follows on from Aviva’s participation in ImmuPharma’s recent £8.4 million fundraising in February the issue and allotment of, in aggregate, 33,158,756 new ordinary shares of 10 pence each in the Company. ImmuPharma now has a total of 121,781,219 Ordinary Shares in issue, which takes Aviva’s current position in the Company to 9.31%.

Full disclosure of the TR1 is shown below:

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ


1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:ⁱⁱ			Immupharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT ISSUE OF EQUITY.			√
3. Full name of person(s) subject to the notification obligation:ⁱⁱⁱ		Aviva plc & its subsidiaries
4. Full name of shareholder(s) (if different from 3.):^iv		Registered Holder: BNY Norwich Union Nominees Limited 628,858* Chase (GA Group) Nominees Limited 9,103,449* *denotes direct interest Chase (GA Group) Nominees Limited 696,778 Chase Nominees Limited 275,292 Vidacos Nominees Limited 528,471
5. Date of the transaction and date on which the threshold is crossed or reached: ^v		04 March 2016
6. Date on which issuer notified:		07 March 2016
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}		8% to 7% Change at Direct Interest Level (Box 8A)

8. Notified details:
A: Voting rights attached to shares ^{viii, ix}
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights ^x
			Direct	Direct ^xi	Indirect^xii	Direct	Indirect
Ordinary Shares GB0033711010	8,140,848	8,140,848	11,232,848	9,732,307	1,500,541	7.99%	1.24%

Click to view all articles for the EPIC: IMM
Or click to view the full company profile:

Learning About Lupus

12th June 2020

May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system

ImmuPharma enter into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million

11th June 2020

ImmuPharma PLC (LON:IMM, the specialist drug discovery and development company, has announced that it has entered into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million (£4.94 million) comprising an

ImmuPharma Change of Registered Office Address

5th June 2020

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

Women 4 times more likely to develop Lupus after stillbirth

4th June 2020

Women who have gone through the trauma of having a stillbirth are four times more likely to develop Lupus than women with an uncomplicated livebirth, according to a University of Manchester study. The researchers found a

ImmuPharma Change of AGM Venue

2nd June 2020

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today announced that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19

Lupus Latest Facts: Causes, Symptoms and Treatments

26th May 2020

Lupus is a relatively rare inflammatory disease. In the US 1.5 million are currently living with the condition. It is an autoimmune disease that can affect various organs including the skin, joints, kidneys, and brain. What

Ghana observes World Lupus Day 2020 with a song release

19th May 2020

A song of hope dubbed ‘At the mention of your name’ has been released to commemorate the 17th global observance of World Lupus Day in Accra. “The song is dedicated to all lupus warriors around the world.

Selena Gomez urges fans to join the fight against Lupus

14th May 2020

US singer Selena Gomez has urged her fans across the world to join the fight against Lupus, an autoimmune disease. The disease leads to the body’s immune system becoming hyperactive, attacking normal and healthy tissues. On

ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor and Ureka

14th May 2020

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today provided a progress update on activities around Covid-19. On 30 March 2020, ImmuPharma announced that it had expanded its pipeline to include three new ‘Anti-Infective’

Understanding Lupus

7th May 2020

Lupus is a chronic (long-term) disease that can cause inflammation and pain in any part of your body. It’s an autoimmune disease, which means that your immune system — the body system that usually fights infections

ImmuPharma remain focussed on achieving full regulatory approval of Lupuzor with US partner Avion

30th April 2020

ImmuPharma plc (LON:IMM), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2019. Key Highlights (including post Period review) · Stable financial performance over the Period

What to know about COVID-19 and lupus

29th April 2020

Lupus is a chronic autoimmune condition in which the immune system attacks its own tissues. People with lupus are at higher risk of infections, and those with lupus who develop COVID-19 may be at higher risk

Frequently asked questions: coronavirus (COVID-19) and lupus

21st April 2020

Our Health Educator Network—health-care professionals and lupus specialists who provide individualized answers—have seen their inquires triple in the last week. The following are questions they’ve been frequently asked and their answers. Should I wear a facemask?

Protecting people with Lupus will help ensure best possible pandemic outcomes for all

15th April 2020

Researchers suggest maintaining disease remission in people with lupus, especially during a pandemic infection, is extremely important to avoid unnecessary office and emergency room visits, and hospitalizations, all of which increase potential exposure to COVID-19. People with lupus

Be sure to check our sister interview main ratings news website